Ethinyl Estradiol

CAS No:
57-63-6 Categories: , ,
  • #LGM Pharma is a Ethinyl Estradiol CAS# 57-63-6 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 57-63-6
  • AHFC code:
  • Synonyms: 17 alpha-Ethinylestradiol 17 alpha-Ethynylestradiol 17 alpha-Ethynyloestradiol 17-ethinyl-3,17-estradiol 17-ethinyl-3,17-oestradiol 17-ethinylestradiol 17alpha-Ethinyl estradiol 17_-ethynylestradiol Ethinyl-Oestranol Ethinylestradiol Ethinylestradiolum [INN-Latin] Ethinylestriol Ethinyloestradiol Ethynyl estradiol Ethynylestradiol Ethynyloestradiol Etinilestradiol [INN-Spanish]
  • ATC Code: G03CA01
  • Chemical Formula: C12H16F3N
  • Molecular Weight: 296.4034
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00977 (APRD00691)
  • SMILES: C[C,]12CC[C,H]3[C,,H](CCC4=C3C=CC(O)=C4)[C,,H]1CC[C,,]2(O)C#C
  • InChl: BFPYWIDHMRZLRN-SLHNCBLASA-N
  • PubChem: 5991
  • IUPAC: (1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol

Additional Details

Indication:
For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
Pharmacodynamics:
Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.
Mode of Action:
Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Metabolism:
Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.
Toxicity:
Oral, mouse LD50: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos